Company Encyclopedia
View More
name
Vera Therapeutics
VERA.US
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company’s lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc.
1.871 T
VERA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Evercore ISI Remains a Buy on Vera Therapeutics (VERA)

    Evercore ISI analyst Gavin Clark-Gartner maintains a Buy rating on Vera Therapeutics with a price target of $95.00. Clark-Gartner, a 5-star analyst with a 25.6% average return, covers the Healthcare sector. The analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $70.82.

    Tip Ranks·
    US
    VERA
    -1.73%
    Tip Ranks·
    US
    VERA
    -1.73%

    Vera Therapeutics Chief Legal Officer Jason Carter Departs

    Vera Therapeutics Inc. announced the departure of Chief Legal Officer Jason Carter, effective December 24, 2025. This information was published via EDGAR by Vera Therapeutics and is for informational purposes only, not financial or legal advice.

    Reuters·
    US
    VERA
    -1.73%
    Reuters·
    US
    VERA
    -1.73%

    Vera Therapeutics Chief Regulatory Officer William D. Turner Reports Sale of Common Shares

    William D. Turner, Chief Regulatory Officer of Vera Therapeutics Inc., reported the sale of common shares of the company. This information was published via EDGAR by Vera Therapeutics and is for informational purposes only.

    Reuters·
    US
    VERA
    -1.73%
    Reuters·
    US
    VERA
    -1.73%

    Dir Enright Buys 5,882 ($250K) Of Vera Therapeutics Inc [VERA]

    Enright Patrick G Director and Beneficial Owner of Vera Therapeutics Inc [VERA] filed a Form 4 on December 15, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/11/25TransactionPurchaseShares5,882Price$42.50Value$249,985Ending Holdings: 5,400,094 (5,882 - Direct, 5,394,212 - Indirect) For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    VERA
    -1.73%
    Reuters·
    US
    VERA
    -1.73%

    Director Patrick G. Enright Reports Acquisition of Vera Therapeutics Common Shares

    Patrick G. Enright, Director of Vera Therapeutics Inc., reported the acquisition of common shares of Vera Therapeutics Inc. This information was disclosed in a recent regulatory filing available via EDGAR, the SEC's system.

    Reuters·
    US
    VERA
    -1.73%
    Reuters·
    US
    VERA
    -1.73%
    Posts
    View More

    Nvidia GTC 2026 will be held March 16-19 in San Jose, CA, with CEO Jensen Huang expected to deliver a keynote highlighting its upcoming Vera Rubin AI chip platform, media report, and also give more de............

    Nvidia CEO Jensen Huang interview with Bloomberg News after 3rd quarter earnings call (Link below). $NVIDIA(NVDA.US) #Semiconductors

    -Question (Q) on Blackwell sales:

    Jensen: “I said, sales are off the...................................................

    $AMD(AMD.US)$Oracle(ORCL.US)Oracle will deploy AMD’s MI450 AI chips in the third quarter of 2026, directly targeting Nvidia’s AI chips. The MI450 is said to be AMD’s most advanced GPU (graphics proces...

    © 2025 Longbridge｜Disclaimer